Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ionis Pharmaceuticals, Inc.    IONS

IONIS PHARMACEUTICALS, INC.

(IONS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2020 10/21/2020 10/22/2020 10/23/2020 10/26/2020 Date
47.4(c) 46.36(c) 47.19(c) 47.34(c) 47.01(c) Last
572 301 981 605 1 015 016 512 821 567 250 Volume
+0.42% -2.19% +1.79% +0.32% -0.70% Change
More quotes
Financials (USD)
Sales 2020 708 M - -
Net income 2020 -71,6 M - -
Net Debt 2020 186 M - -
P/E ratio 2020 -94,9x
Yield 2020 -
Sales 2021 840 M - -
Net income 2021 -53,0 M - -
Net Debt 2021 203 M - -
P/E ratio 2021 -153x
Yield 2021 -
Capitalization 6 613 M 6 613 M -
EV / Sales 2020 9,61x
EV / Sales 2021 8,12x
Nbr of Employees 817
Free-Float 95,0%
More Financials
Company
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of... 
More about the company
Notations Surperformance© of Ionis Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about IONIS PHARMACEUTICALS, INC.
10/23IONIS PHARMACEUTICALS : third novel antisense medicine for ALS, its first design..
AQ
10/22IONIS PHARMACEUTICALS : to hold third quarter 2020 financial results webcast
AQ
10/22IONIS PHARMACEUTICALS : ' third novel antisense medicine for ALS, its first desi..
PR
10/21IONIS PHARMACEUTICALS : to hold third quarter 2020 financial results webcast
PR
10/16IONIS PHARMACEUTICALS : antisense medicine being evaluated in an investigator-in..
AQ
10/15IONIS PHARMACEUTICALS : antisense medicine being evaluated in an investigator-in..
PR
10/14IONIS PHARMACEUTICALS : inhaled antisense medicine demonstrates potential as a n..
AQ
10/13IONIS PHARMACEUTICALS : completes acquisition of Akcea Therapeutics
AQ
10/13IONIS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, ..
AQ
10/02IONIS PHARMACEUTICALS : Chief Scientific Officer Frank Bennett receives Lifetime..
AQ
10/01IONIS PHARMACEUTICALS : Chief Scientific Officer Frank Bennett receives Lifetime..
PR
10/01IONIS PHARMACEUTICALS : treatment for Alexander disease receives orphan drug des..
AQ
10/01IONIS PHARMACEUTICALS : and Genuity Science announce agreement designed to rapid..
PR
09/30IONIS PHARMACEUTICALS : treatment for Alexander disease receives orphan drug des..
PR
09/03IONIS PHARMACEUTICALS : to present at upcoming virtual investor conferences
PR
More news
News in other languages on IONIS PHARMACEUTICALS, INC.
2019BB Biotech creuse sa perte au deuxième trimestre
2019IONIS PHARMACEUTICALS INC : Veröffentlichung des Quartalsergebnisses
2019IONIS PHARMACEUTICALS INC : publication des résultats trimestriels
2019IONIS PHARMACEUTICALS INC : Veröffentlichung des Jahresergebnisses
2019IONIS PHARMACEUTICALS INC : publication des résultats annuels
More news
Chart IONIS PHARMACEUTICALS, INC.
Duration : Period :
Ionis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IONIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 67,40 $
Last Close Price 47,34 $
Spread / Highest target 153%
Spread / Average Target 42,4%
Spread / Lowest Target -59,9%
EPS Revisions
Managers
NameTitle
Brett P. Monia Chief Executive Officer & Director
Stanley T. Crooke Executive Chairman
Joel Edwards Vice President-Corporate & Commercial Operations
Elizabeth L. Hougen Chief Financial Officer & SVP-Finance
C. Frank Bennett Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
IONIS PHARMACEUTICALS, INC.-21.64%6 613
LONZA GROUP AG62.80%47 152
SEAGEN INC.72.54%34 263
IQVIA HOLDINGS INC.8.39%32 108
CELLTRION, INC.31.49%28 160
MODERNA, INC.260.58%27 830